Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant

Ain Shams University

Status and phase: Completed; Early Phase 1

Conditions: Liver Transplant Disorder

Treatments: Drug: Mannitol; Other: 0.9% normal saline

Study type: Interventional

Funder types: Other

Identifiers

NCT05277623

R 42/ 2022

Details and patient eligibility

About

Postreperfusion syndrome during living liver transplants remains a serious concern for transplant anesthesiologists. This syndrome is responsible for decreases in systemic blood pressure, systemic vascular resistance, and cardiac output and can even lead to cardiac arrest. Delayed graft function and primary graft nonfunction are closely related to postreperfusion syndrome (Therefore, attenuating the syndrome during anesthesia is of great importance.

Enrollment: 60 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with end-stage liver disease who will undergo living donor transplantation.

Exclusion criteria

• Patients with a history of portopulmonary hypertension.
• Hepatopulmonary syndrome.
• Cirrhotic cardiomyopathy.
• Hepatorenal syndrome types 1 and 2.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

mannitol group

Active Comparator group

Treatment:

Drug: Mannitol

control group

Placebo Comparator group

Treatment:

Other: 0.9% normal saline